Díaz AMA, Revilla PF, Rodríguez RJ, Sánchez RJP, Boone EA, Zamora LJ

Language: Spanish
References: 14
Page: 54-58
PDF size: 117.63 Kb.

ABSTRACT

The study was designed to determine the association between remifentanyl-dexmedetomidine and the influence in sevofluorane’s Minimum Alveolar Concentration (MAC). Material and methods: 48 patients were scheduled for elective surgery, ASA I-II and distributed in two groups: 1 sevofluorane-dexmedetomidine, and 2 sevofluorane-remifentanyl-dexmedetomidine group. We gave an initial induction with remifentanyl 0.40 µg/kg/min in a intravenous infusion and maintenance in a dose dependent mode, propofol 2 mg/kg and rocuronium 500-600 µg/kg for endotracheal intubation. In the second group we also administered 20 minutes before the induction dexmedetomidine 0.7 µg/kg initially and 0.35 µg/kg/h in intravenous infusion. We evaluated the requirements of sevofluorane, remifentanyl and dexmedetomidine during the anesthesia period. Results: The sevofluorane MAC decrease a 25% with remifentanyl and 40% in the remifentanyl-dexmedetomidine group. In the hemodynamic parameters and the BIS did not have a significant change in any group. The plasmatic concentration of remifentanyl was 7.1- 8.3 ng/mL and dexmedetomidine 0.45 ng/mL. Discussion: The sevofluorane MAC reduction with the remifentanyl-dexmedetomidine association is similar to previous studies with opioids and alpha-2 agonists. The results are important for determining different dosage schemes to achieve a suitable anesthetic state, bringing hemodynamic stability and a fast recuperation.

REFERENCES

1. Olkkola KT. Drug interactions. Curr Opin Anesthesiol 2001; 14: 411-416.

2. Stoelting R. Pharmacology and Physiology in Anesthetic Practice. Philadelphia, PA: Lippincott-Raven Publishers; 1999: 3. p. 77-112.

3. Evers A. Anesthetic Pharmacology. New York, NY: Churchill Livingstone; 2004: 1. p. 3-20, 457-471.

4. Kamibayashi T, Maze M. Clinical uses of a2-adrenergic agonist. Anesthesiology 2000; 93: 1345-1349.

5. Kern ES. Opioid-hypnotic synergy. Anesthesiology 2004; 100: 1373-1381.

6. Lang E. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 1996; 85: 721-728.

7. Guy J, Comparison of remifentanil and fentanil in patients undergoing craniotomy for supratentorial space occupying lesions. Anesthesiology 1997; 86: 514-524.

8. Sandeep C. A response surface model with remifentanil and sevoflurane as prototypes. Anesthesiology 2006; 105: 267-278.

9. Song D. Remifentanil infusion facilitates rearly recovery for obese outpatients undergoing laparoscopic cholecystectomy. Anesth Analg 2000; 90: 1111-1113.

10. Hall JE. Sedative, amnesic and analgesic properties of small dose dexmedetomidine infusions. Anesth Analg 2000; 90: 699-705.

11. Khan ZP. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. Br J Anaesth 1999; 83: 372-380.

12. Randel GI. Remifentanil blood concentration effects relationship at intubation and skin incision in surgical patients compared to alfentanil. Anesthesiology 1994; 81: A375.

13. Talke P. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg 2000; 834-839.

14. Dahaba AA. Different Conditions that could result in the Biespectral Index indicating an incorrect hypnotic state. Anesthesiology 2005; 101: 765-773.